



April 15, 2021

Dear Muscular Dystrophy Canada,

As per your request, Roche Canada is pleased to share with you that on April 14, 2021, Health Canada approved Evrysdi<sup>®</sup> (risdiplam) for Spinal Muscular Atrophy (SMA) in patients two months and older.

We are extremely proud to bring this medicine to the SMA community – and to alleviate the burden of those living with this highly disabling, rare neurological disorder. With the introduction of EVRYSDI, our aim is to help improve the lives of Canadians with SMA.

While today marks a significant milestone for the SMA community, we are keenly aware of the persisting unmet need that remains in access to treatment options. We are committed to working closely with regulatory bodies and provincial payers to enable broad and rapid access for those in need.

We express our sincere gratitude and we thank you for your partnership, the trust you have placed in us and your unyielding commitment to achieve this monumental milestone. Today we celebrate our partnership and our collective achievement.

Please join us in celebrating this important milestone for Canadian patients and their families, and thank you for your relentless support and commitment to SMA families in Canada.

If you have any other questions about this update, please do not hesitate to contact me.

You can read more about the approval [here](#).

Sincerely,

*Sarah Khan*

Sarah Khan,  
Patient Experience Manager, Rare Conditions